Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
| dupilumab [2025/03/07 01:44] – created Scott Larson | dupilumab [2025/06/14 04:11] (current) – [Resources] Scott Larson | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Dupilumab ====== | ====== Dupilumab ====== | ||
| - | a.k.a. Dupixent | + | a.k.a. Dupixent |
| ====Ocular Complications==== | ====Ocular Complications==== | ||
| - | * Reported in those with atopic dermatitis | + | * Reported in clinical trials |
| * conjunctivitis | * conjunctivitis | ||
| * keratitis | * keratitis | ||
| Line 15: | Line 15: | ||
| ==== Resources ==== | ==== Resources ==== | ||
| - | [[https://pubmed.ncbi.nlm.nih.gov/35181280/| Wu D et al. Dupilumab-associated ocular manifestations: | + | [[https://1drv.ms/b/c/31d83ae8e55e0542/EW0RbSa-6SpHloMpdwjZYugBzs9tLRJYcJbgGCtykQccbw? |
| - | {{tag>drug}} | + | {{tag>drugs}} |